Understanding the Impact of Low BSA Psoriasis and Its Disease Burden

What is BSA and how is it used to classify psoriasis severity?

BSA, or body surface area, is a measure used to classify psoriasis severity, where less than 3% BSA is considered mild, 3-10% moderate, and over 10% severe. More details can be found at psoriasis.org.

Why is the finding about low BSA psoriasis significant?

This finding is significant because it suggests that even psoriasis affecting a small body surface area can have a high disease burden, challenging the traditional classification system and highlighting the need for personalized treatment approaches.

Who is involved in the search for more efficacious psoriasis treatments?

Companies like Soligenix Inc. (NASDAQ: SNGX) are involved in the search for more effective psoriasis treatments, as mentioned in the content. Learn more about Soligenix at biomedwire.com.

What are the implications of this study for psoriasis patients?

The study implies that psoriasis patients, even those with low BSA, may experience a significant disease burden, suggesting the need for comprehensive assessment and treatment beyond just BSA measurements.

Where can I find more information about this study?

More information about the study can be found by following the ‘Read More’ link in the content at biomedwire.com.

What is BioMedWire and how does it relate to this content?

BioMedWire is a specialized communications platform focusing on biotechnology and life sciences, which published this content. For more about BioMedWire, visit biomedwire.com.

How can I receive updates from BioMedWire?

To receive SMS alerts from BioMedWire, text ‘Biotech’ to 888-902-4192 (U.S. Mobile Phones Only), as mentioned in the content.